Rapid Procedure Noninferior for Extended-Release Naltrexone Initiation
By Elana Gotkine HealthDay Reporter
THURSDAY, May 9, 2024 -- For patients with opioid use disorder (OUD), a rapid procedure (RP) is noninferior to a standard procedure for initiation of extended-release (XR) naltrexone, according to a study published online May 8 in JAMA Network Open.
Matisyahu Shulman, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues compared the effectiveness of SP, with approximately five-day buprenorphine taper followed by a seven- to 10-day opioid free period, to the effectiveness of RP, defined as one day of buprenorphine and one opioid-free day, for XR naltrexone initiation. Units using the SP were randomly assigned to implement the RP at 14-week intervals. Participants admitted with OUD received the procedure that was being delivered at the unit at the time of admission.
A total of 415 patients with OUD were enrolled. The researchers found that the rate of successful initiation of XR naltrexone was 62.7 percent in the RP group, which was noninferior to the rate of 35.8 percent in the SP group (odds ratio, 3.60). There was no significant difference observed between the groups in withdrawal. Targeted safety events and serious adverse events occurred rarely but were more common with RP than SP.
"In future studies, the implementation strategies used in the present trial could be broadened to encompass initiation of buprenorphine and methadone, addressing the larger goal of maximizing the proportion of patients with OUD admitted to inpatient or residential treatment who emerge stabilized on medications for OUD," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Alkermes, which together with Emmes Company donated Vivitrol (naltrexone for XR injectable suspension) for the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Hospital Addiction Consultation Service Aids Opioid Use Disorder
WEDNESDAY, April 16, 2025 -- A hospital-based addiction consultation service can improve receipt of evidence-based treatment for people with opioid use disorder (OUD), according...
Stimulant Involvement in Opioid OD Death Higher for Those in Physically Demanding Jobs
TUESDAY, April 1, 2025 -- A higher percentage of individuals who have psychostimulant involvement in synthetic opioid overdose deaths tend to work in physically demanding...
Evidence Supports Continuing Buprenorphine for Acute Pain in Those With Opioid Use Disorder
MONDAY, March 31, 2025 -- For patients with opioid use disorder (OUD), evidence supports continuation of buprenorphine during episodes of acute pain, but overall evidence for pain...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.